ATE483463T1 - Pyridonsulfonamide und pyridonsulfamide als mek- hemmer - Google Patents
Pyridonsulfonamide und pyridonsulfamide als mek- hemmerInfo
- Publication number
- ATE483463T1 ATE483463T1 AT07760859T AT07760859T ATE483463T1 AT E483463 T1 ATE483463 T1 AT E483463T1 AT 07760859 T AT07760859 T AT 07760859T AT 07760859 T AT07760859 T AT 07760859T AT E483463 T1 ATE483463 T1 AT E483463T1
- Authority
- AT
- Austria
- Prior art keywords
- pyridone
- sulfonamide
- mek inhibitors
- mek
- inhibitors
- Prior art date
Links
- -1 PYRIDONE SULFONAMIDE Chemical class 0.000 title abstract 3
- 229940124530 sulfonamide Drugs 0.000 title 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- XSJZFXKWCCMFKJ-UHFFFAOYSA-N O=S(=O)NC1=CC=CNC1NC1=CC=CC=C1 Chemical class O=S(=O)NC1=CC=CNC1NC1=CC=CC=C1 XSJZFXKWCCMFKJ-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79312906P | 2006-04-18 | 2006-04-18 | |
PCT/US2007/066894 WO2007121481A2 (en) | 2006-04-18 | 2007-04-18 | Pyridone sulfonamides and pyridone sulfamides as mek inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE483463T1 true ATE483463T1 (de) | 2010-10-15 |
Family
ID=38610466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07760859T ATE483463T1 (de) | 2006-04-18 | 2007-04-18 | Pyridonsulfonamide und pyridonsulfamide als mek- hemmer |
Country Status (16)
Country | Link |
---|---|
US (2) | US7897624B2 (de) |
EP (1) | EP2012786B1 (de) |
JP (1) | JP5269762B2 (de) |
KR (1) | KR101391461B1 (de) |
CN (1) | CN101454004B (de) |
AT (1) | ATE483463T1 (de) |
AU (1) | AU2007237901B2 (de) |
BR (1) | BRPI0710817A2 (de) |
CA (1) | CA2649122C (de) |
DE (1) | DE602007009663D1 (de) |
EA (1) | EA016674B1 (de) |
ES (1) | ES2354182T3 (de) |
HK (1) | HK1128617A1 (de) |
IL (1) | IL194595A (de) |
MX (1) | MX2008013097A (de) |
WO (1) | WO2007121481A2 (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA009478B1 (ru) * | 2002-08-23 | 2008-02-28 | Ардеа Байосайенсиз, Инк. | Ненуклеозидные ингибиторы обратной транскриптазы |
US7429667B2 (en) * | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
US9095581B2 (en) | 2005-07-21 | 2015-08-04 | Ardea Biosciences, Inc. | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof |
US7842836B2 (en) | 2006-04-11 | 2010-11-30 | Ardea Biosciences | N-aryl-N'alkyl sulfamides as MEK inhibitors |
DE602007009663D1 (de) | 2006-04-18 | 2010-11-18 | Ardea Biosciences Inc | Pyridonsulfonamide und pyridonsulfamide als mek-hemmer |
US8509487B2 (en) * | 2007-04-19 | 2013-08-13 | Avago Technologies General Ip (Singapore) Pte. Ltd. | System and method for optically measuring a parameter of an object |
CA2924418A1 (en) * | 2007-07-30 | 2009-02-05 | Jean-Michel Vernier | Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same |
TW201038267A (en) * | 2008-04-21 | 2010-11-01 | Novartis Ag | Heterocyclic compounds as MEK inhibitors |
MX2011001127A (es) | 2008-08-04 | 2011-03-21 | Merck Patent Gmbh | Compuestos novedosos de fenilamino-isonicotinamida. |
JP5651125B2 (ja) | 2008-12-10 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Mek阻害剤に対する耐性を付与するmek突然変異 |
UY32486A (es) * | 2009-03-11 | 2010-10-29 | Ardea Biosciences Inc | Tratamiento del cáncer de páncreas |
WO2010108652A1 (en) * | 2009-03-27 | 2010-09-30 | Ardea Biosciences Inc. | Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors |
CN102459188A (zh) * | 2009-06-15 | 2012-05-16 | 凯美隆(北京)药业技术有限公司 | 新型6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂 |
CN102134218A (zh) * | 2009-06-15 | 2011-07-27 | 凯美隆(北京)药业技术有限公司 | 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂 |
TWI524890B (zh) | 2009-07-24 | 2016-03-11 | 亞德生化公司 | (r)-n-(3,4-二氟-2-(2-氟-4-碘苯胺基)-6-甲氧基苯基)-1-(2,3-二羥丙基)環丙烷-1-磺醯胺及(s)-n-(3,4-二氟-2-(2-氟-4-碘苯胺基)-6-甲氧基苯基)-1-(2,3-二羥丙基)環丙烷-1-磺醯胺之製備 |
US8349832B2 (en) * | 2009-09-02 | 2013-01-08 | Canthera Therapeutics | Compounds and compositions for treating cancer |
US8318737B2 (en) | 2009-09-02 | 2012-11-27 | Canthera Therapeutics Inc. | Compounds and compositions for treating cancer |
ES2534358T3 (es) | 2009-10-13 | 2015-04-21 | Allomek Therapeutics, Llc | Inhibidores novedosos de MEK útiles en el tratamiento de enfermedades |
WO2011054828A1 (en) | 2009-11-04 | 2011-05-12 | Novartis Ag | Heterocyclic sulfonamide derivatives useful as mek inhibitors |
MX340392B (es) | 2010-02-25 | 2016-07-06 | Dana Farber Cancer Inst Inc | Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf. |
CA2791247C (en) | 2010-03-09 | 2019-05-14 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
US9845489B2 (en) | 2010-07-26 | 2017-12-19 | Biomatrica, Inc. | Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
WO2012018638A2 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
CN102358730A (zh) * | 2011-08-24 | 2012-02-22 | 济南赛文医药技术有限公司 | 一种小分子mek蛋白激酶抑制剂 |
CN103204825B (zh) | 2012-01-17 | 2015-03-04 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途 |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
WO2014100755A2 (en) | 2012-12-20 | 2014-06-26 | Biomatrica, Inc. | Formulations and methods for stabilizing pcr reagents |
EP3007556B1 (de) | 2013-06-13 | 2020-05-20 | Biomatrica, INC. | Zellstabilisierung |
CN106572650B (zh) | 2014-06-10 | 2021-08-31 | 生物马特里卡公司 | 在环境温度下稳定凝血细胞 |
WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
AU2016368265B2 (en) | 2015-12-08 | 2021-10-28 | Biomatrica, Inc. | Reduction of erythrocyte sedimentation rate |
US10366774B2 (en) | 2016-09-27 | 2019-07-30 | Spin Memory, Inc. | Device with dynamic redundancy registers |
US10489245B2 (en) | 2017-10-24 | 2019-11-26 | Spin Memory, Inc. | Forcing stuck bits, waterfall bits, shunt bits and low TMR bits to short during testing and using on-the-fly bit failure detection and bit redundancy remapping techniques to correct them |
US10411185B1 (en) | 2018-05-30 | 2019-09-10 | Spin Memory, Inc. | Process for creating a high density magnetic tunnel junction array test platform |
CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5596008A (en) * | 1995-02-10 | 1997-01-21 | G. D. Searle & Co. | 3,4-Diaryl substituted pyridines for the treatment of inflammation |
US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
CA2218503C (en) * | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
EP0818442A3 (de) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclische Sulphonderivate als Metalloproteinase-Inhibitoren und zur Hemmung der Produktion von Tumornekrosefaktor |
DE69712496T2 (de) | 1996-07-18 | 2002-08-29 | Pfizer | Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren |
KR20000068248A (ko) | 1996-08-23 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 아릴설포닐아미노 하이드록삼산 유도체 |
PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
US6303636B1 (en) | 1997-02-03 | 2001-10-16 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
AU5493598A (en) | 1997-02-07 | 1998-08-26 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
BR9807678A (pt) | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
CA2299355C (en) | 1997-08-08 | 2005-09-27 | Pfizer Products Inc. | Aryloxyarylsulfonylamino hydroxamic acid derivatives |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
UA60365C2 (uk) * | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
EP1004578B1 (de) | 1998-11-05 | 2004-02-25 | Pfizer Products Inc. | 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate |
GB9912961D0 (en) | 1999-06-03 | 1999-08-04 | Pfizer Ltd | Metalloprotease inhibitors |
US6511993B1 (en) * | 1999-06-03 | 2003-01-28 | Kevin Neil Dack | Metalloprotease inhibitors |
DE60122176T2 (de) * | 2000-09-15 | 2007-07-05 | Vertex Pharmaceuticals Inc., Cambridge | Isoxazole und ihre verwendung als erk-inhibitoren |
EP1337524A1 (de) * | 2000-11-02 | 2003-08-27 | AstraZeneca AB | Substituierte chinoline als antitumormittel |
TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
EP2130536B1 (de) * | 2002-03-13 | 2013-05-08 | Array Biopharma, Inc. | N3-alkylierte Benzimidazolderivate als MEK-Inhibitoren |
US6989451B2 (en) * | 2002-06-04 | 2006-01-24 | Valeant Research & Development | Heterocyclic compounds and uses thereof |
WO2004011461A1 (en) * | 2002-07-25 | 2004-02-05 | Pfizer Products Inc. | Isothiazole derivatives useful as anticancer agents |
JP2005162727A (ja) * | 2003-03-18 | 2005-06-23 | Sankyo Co Ltd | スルファミド誘導体及びその医薬組成物 |
BRPI0416692A (pt) * | 2003-11-19 | 2007-01-30 | Array Biopharma Inc | inibidores heterocìclicos de mek e métodos de emprego destes |
JP2006083133A (ja) * | 2004-09-17 | 2006-03-30 | Sankyo Co Ltd | スルファミド誘導体医薬組成物 |
JP2006083137A (ja) * | 2004-09-17 | 2006-03-30 | Sankyo Co Ltd | 免疫抑制剤 |
US8101799B2 (en) * | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
DE602007009663D1 (de) | 2006-04-18 | 2010-11-18 | Ardea Biosciences Inc | Pyridonsulfonamide und pyridonsulfamide als mek-hemmer |
-
2007
- 2007-04-18 DE DE602007009663T patent/DE602007009663D1/de active Active
- 2007-04-18 EA EA200870446A patent/EA016674B1/ru not_active IP Right Cessation
- 2007-04-18 JP JP2009506751A patent/JP5269762B2/ja not_active Expired - Fee Related
- 2007-04-18 CN CN2007800193159A patent/CN101454004B/zh not_active Expired - Fee Related
- 2007-04-18 AU AU2007237901A patent/AU2007237901B2/en not_active Ceased
- 2007-04-18 US US11/737,109 patent/US7897624B2/en not_active Expired - Fee Related
- 2007-04-18 MX MX2008013097A patent/MX2008013097A/es active IP Right Grant
- 2007-04-18 WO PCT/US2007/066894 patent/WO2007121481A2/en active Application Filing
- 2007-04-18 EP EP07760859A patent/EP2012786B1/de active Active
- 2007-04-18 ES ES07760859T patent/ES2354182T3/es active Active
- 2007-04-18 AT AT07760859T patent/ATE483463T1/de not_active IP Right Cessation
- 2007-04-18 BR BRPI0710817-6A patent/BRPI0710817A2/pt not_active IP Right Cessation
- 2007-04-18 CA CA2649122A patent/CA2649122C/en not_active Expired - Fee Related
-
2008
- 2008-10-07 IL IL194595A patent/IL194595A/en not_active IP Right Cessation
- 2008-11-18 KR KR1020087028158A patent/KR101391461B1/ko not_active IP Right Cessation
-
2009
- 2009-07-14 HK HK09106325.4A patent/HK1128617A1/xx not_active IP Right Cessation
-
2011
- 2011-01-19 US US13/009,052 patent/US8716318B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101454004B (zh) | 2013-12-04 |
WO2007121481A2 (en) | 2007-10-25 |
EP2012786B1 (de) | 2010-10-06 |
KR20090005193A (ko) | 2009-01-12 |
IL194595A (en) | 2015-04-30 |
CA2649122A1 (en) | 2007-10-25 |
US20110112152A1 (en) | 2011-05-12 |
CA2649122C (en) | 2015-06-30 |
HK1128617A1 (en) | 2009-11-06 |
WO2007121481A8 (en) | 2008-10-16 |
BRPI0710817A2 (pt) | 2011-08-23 |
CN101454004A (zh) | 2009-06-10 |
MX2008013097A (es) | 2008-10-27 |
US7897624B2 (en) | 2011-03-01 |
EA200870446A1 (ru) | 2009-04-28 |
AU2007237901B2 (en) | 2012-07-05 |
US8716318B2 (en) | 2014-05-06 |
WO2007121481A3 (en) | 2008-05-22 |
US20070244164A1 (en) | 2007-10-18 |
AU2007237901A1 (en) | 2007-10-25 |
DE602007009663D1 (de) | 2010-11-18 |
JP5269762B2 (ja) | 2013-08-21 |
EP2012786A4 (de) | 2010-02-24 |
EA016674B1 (ru) | 2012-06-29 |
JP2009534408A (ja) | 2009-09-24 |
ES2354182T3 (es) | 2011-03-10 |
EP2012786A2 (de) | 2009-01-14 |
KR101391461B1 (ko) | 2014-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE483463T1 (de) | Pyridonsulfonamide und pyridonsulfamide als mek- hemmer | |
MX2008002114A (es) | Inhibidores de n-(arilamino)-sulfonamida de mek. | |
EA200900959A1 (ru) | Ингибиторы мек | |
WO2007121269A3 (en) | N-aryl-n'alkyl sulfamides as mek inhibitors | |
EA200900781A1 (ru) | 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды | |
EA200701918A1 (ru) | Белок липокалин | |
DK1784426T3 (da) | Humaniserede anti-beta7-antagonister og anvendelser deraf | |
ATE447559T1 (de) | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen | |
EA200701396A1 (ru) | Триазолофталазины в качестве ингибиторов pde-2 | |
EA200970738A1 (ru) | Ингибиторы активности akt | |
EA201000494A1 (ru) | Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4 | |
MX2008001538A (es) | Aril piridinas y metodos para su uso. | |
EA201390609A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
EA200801362A1 (ru) | Пиримидинил бензотиофеновые соединения | |
NO20076413L (no) | Multisykliske forbindelser og fremgangsmater for deres anvendelse | |
CR9869A (es) | Compuestos activos en ppar | |
EA201000888A1 (ru) | 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы в качестве гербицидов | |
EA200901109A1 (ru) | Применение n-фениламидинов в качестве гербицидов | |
EA200700400A1 (ru) | Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии | |
EA201000258A1 (ru) | Новые гербициды | |
EA200602281A1 (ru) | Гетероарилсульфоны и сульфонамиды и их терапевтические применения | |
EA200601855A1 (ru) | Гербицидоактивные 3-амино-2-тиометилбензоилпиразолы | |
NO20083751L (no) | Metoder for behandling av kognitive og andre sykdommer | |
EA201000069A1 (ru) | Новые гербициды | |
BRPI0615141A2 (pt) | inibidores pentacìclicos de quinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |